Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes

European Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 113-117

  Miura, Masatomo ^a   Satoh, Shigeru ^b   Tada, Hitoshi ^a   Habuchi, Tomonori ^b   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY   (Japan)

Author keywords

CYP2C19; CYP3A4; Enantiomer; Rabeprazole; Rabeprazole thioether

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; NORRABEPRAZOLE THIOETHER; RABEPRAZOLE; RABEPRAZOLE THIOETHER; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG OXIDATION; ENANTIOMER; ENZYME ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEREOCHEMISTRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; PROTON PUMPS; STEREOISOMERISM; SULFIDES;

EID: 33645415463     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0077-8     Document Type: Article

References (11)

1. Prakash A, Faulds D (1998) Rabeprazole. Drugs 55:261-267
2. Morii M, Takata H, Fujisaki H, Takeguchi N (1990) The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. Biochem Pharmacol 39:661-667
3. Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N (1991) Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 42:321-328
4. Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13:27-36
5. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 58:143-154
6. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA (1996) Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6:81-91
7. Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, Shimamura Y, Morishita N (1994) Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 32:466-473
8. Miura M, Kagaya H, Tada H, Sagae Y, Satoh S, Habuchi T, Suzuki T (2005) Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica 35:479-486
9. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4:879-885
10. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K (2001) CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721-727
11. Rane A, Wilkinson GR, Shand DG (1977) Prediction of hepatic extraction ratio from in vivo measurement of intrinsic clearance. J Pharmacol Exp Ther 200:420-424